EDITION:

Search
Search
Close this search box.

Positive results for cannabinoid targeting multi-billion pain market

Oxford Cannabinoid Technologies has announced positive data from a pre-clinical study of its lead compound, OCT461201.

The compound is targeting the US$1.61bn (~£1.22bn) global Chemotherapy Induced Peripheral Neuropathy (CIPN) treatment market. The condition is characterised by pain, numbness and tingling in the extremities from the neurotoxic effects of common chemotherapeutic drugs.

With an estimated 60 per cent of people undergoing chemotherapy being affected by CIPN by three months of treatment, the market is forecast to reach $2.37bn by 2027.

Oxford Cannabinoid Technologies’ study demonstrated that its OCT461201 compound successfully reduced pain in a pre-clinical animal model of CIPN induced by the commonly used chemotherapy agent, paclitaxe. 

Chief executive John Lucas commented: “To obtain such a positive result in this study is significant and provides further evidence that OCT461201 could be an effective therapy in the treatment of CIPN in cancer patients. 

Read more: Oxford Cannabinoid Technologies sees positive progression

“Based on previously completed pre-clinical safety experiments, the directors believe the administered dose of OCT461201 could have been increased by over three times. The results of this study demonstrate the opportunities open to OCT461201 in treating a major and common side effect experienced by so many cancer patients and we are more excited than ever to be starting Phase I clinical trials early next year. 

“These latest results reaffirm the potential of OCT461201 across multiple indications.”

In the study, OCT461201 significantly reduced pain from two common symptoms of CIPN – light touch (mechanical allodynia) and heat or cold (thermal hyperalgesia) – compared to untreated animals.

The company highlights that there is an urgent global need for new therapies to treat CIPN as there are currently none approved for this condition. The current standard of care is the off-label use of gabapentinoids (gabapentin and pregabalin) and antidepressants (e.g. duloxetine), drugs associated with serious side effects.

The clinical effectiveness of these off-label drugs is inadequate, leaving cancer patients in pain, with a reduced quality of life and the prospect of having to change or stop chemotherapy altogether.

The company recently announced that it has signed a number of drug development agreements that will support its activities for the pre-clinical development of cannabinoids targeting pain, neurology, and inflammation.

[activecampaign form=31]

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?